LOL please read the post to which you have replied before replying.
And you will see that what the FDA wrote, that this analysis was not stat. sig., is a real ISSUE for Cytodyn, COMPROMISES the entire study about Leronlimab, and EXPLAINS why the stock has lost -96% since then.